世界のムコ多糖症治療薬市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)

GlobalInfoResearchが発行した調査報告書(GIR20SP05927)
◆英語タイトル:Global Mucopolysaccharidosis Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025
◆商品コード:GIR20SP05927
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2020年9月23日(※2024年版があります。お問い合わせください。)
◆ページ数:107
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療、製薬、バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、ムコ多糖症治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。ムコ多糖症治療薬の種類別市場規模(静脈内、脳室内(ICV))、用途別市場規模(病院、クリニック、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Shire (Takeda Pharmaceutical Company Limited)、Abeona Therapeutics Inc.、REGENXBIO Inc.、Denali Therapeutics、Lysogene、ArmaGen、Genzyme Corporation、BioMarin、Sangamo Therapeutics、Ultragenyx Pharmaceutical
・地域別グローバル市場分析 2015年-2020年
・ムコ多糖症治療薬の北米市場(アメリカ、カナダ、メキシコ)
・ムコ多糖症治療薬のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・ムコ多糖症治療薬のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・ムコ多糖症治療薬の南米市場(ブラジル、アルゼンチン)
・ムコ多糖症治療薬の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:静脈内、脳室内(ICV)
・用途別分析:病院、クリニック、その他
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The Mucopolysaccharidosis Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The most likely (base case) scenario is that the global Mucopolysaccharidosis Therapeutics sales will be xx in 2020 from Mucopolysaccharidosis Therapeutics million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Mucopolysaccharidosis Therapeutics market size is expected to grow at xx% or more annually for the next five years.

This report also researches and evaluates the impact of Covid-19 outbreak on the Mucopolysaccharidosis Therapeutics industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Mucopolysaccharidosis Therapeutics and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Market segmentation
Mucopolysaccharidosis Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Mucopolysaccharidosis Therapeutics market has been segmented into:
Intravenous
Intracerebroventricular (ICV)

By Application, Mucopolysaccharidosis Therapeutics has been segmented into:
Hospital
Clinic
Other

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Mucopolysaccharidosis Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Mucopolysaccharidosis Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Mucopolysaccharidosis Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Mucopolysaccharidosis Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Mucopolysaccharidosis Therapeutics Market Share Analysis
Mucopolysaccharidosis Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Mucopolysaccharidosis Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Mucopolysaccharidosis Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Mucopolysaccharidosis Therapeutics are:
Shire (Takeda Pharmaceutical Company Limited)
Abeona Therapeutics Inc.
REGENXBIO Inc.
Denali Therapeutics
Lysogene
ArmaGen
Genzyme Corporation
BioMarin
Sangamo Therapeutics
Ultragenyx Pharmaceutical
Among other players domestic and global, Mucopolysaccharidosis Therapeutics market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

【レポートの目次】

1 Mucopolysaccharidosis Therapeutics Market Overview
1.1 Product Overview and Scope of Mucopolysaccharidosis Therapeutics
1.2 Classification of Mucopolysaccharidosis Therapeutics by Type
1.2.1 Global Mucopolysaccharidosis Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type in 2019
1.2.3 Intravenous
1.2.4 Intracerebroventricular (ICV)
1.3 Global Mucopolysaccharidosis Therapeutics Market by Application
1.3.1 Overview: Global Mucopolysaccharidosis Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Mucopolysaccharidosis Therapeutics Market by Regions
1.4.1 Global Mucopolysaccharidosis Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Mucopolysaccharidosis Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Mucopolysaccharidosis Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Mucopolysaccharidosis Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Mucopolysaccharidosis Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Mucopolysaccharidosis Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Mucopolysaccharidosis Therapeutics Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Mucopolysaccharidosis Therapeutics Industry Impact
1.5.1 COVID-19 Potential Implications for the Mucopolysaccharidosis Therapeutics
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Mucopolysaccharidosis Therapeutics
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Shire (Takeda Pharmaceutical Company Limited)
2.1.1 Shire (Takeda Pharmaceutical Company Limited) Details
2.1.2 Shire (Takeda Pharmaceutical Company Limited) Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Shire (Takeda Pharmaceutical Company Limited) SWOT Analysis
2.1.4 Shire (Takeda Pharmaceutical Company Limited) Product and Services
2.1.5 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Abeona Therapeutics Inc.
2.2.1 Abeona Therapeutics Inc. Details
2.2.2 Abeona Therapeutics Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Abeona Therapeutics Inc. SWOT Analysis
2.2.4 Abeona Therapeutics Inc. Product and Services
2.2.5 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 REGENXBIO Inc.
2.3.1 REGENXBIO Inc. Details
2.3.2 REGENXBIO Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 REGENXBIO Inc. SWOT Analysis
2.3.4 REGENXBIO Inc. Product and Services
2.3.5 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Denali Therapeutics
2.4.1 Denali Therapeutics Details
2.4.2 Denali Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Denali Therapeutics SWOT Analysis
2.4.4 Denali Therapeutics Product and Services
2.4.5 Denali Therapeutics Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Lysogene
2.5.1 Lysogene Details
2.5.2 Lysogene Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Lysogene SWOT Analysis
2.5.4 Lysogene Product and Services
2.5.5 Lysogene Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 ArmaGen
2.6.1 ArmaGen Details
2.6.2 ArmaGen Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 ArmaGen SWOT Analysis
2.6.4 ArmaGen Product and Services
2.6.5 ArmaGen Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Genzyme Corporation
2.7.1 Genzyme Corporation Details
2.7.2 Genzyme Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Genzyme Corporation SWOT Analysis
2.7.4 Genzyme Corporation Product and Services
2.7.5 Genzyme Corporation Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 BioMarin
2.8.1 BioMarin Details
2.8.2 BioMarin Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 BioMarin SWOT Analysis
2.8.4 BioMarin Product and Services
2.8.5 BioMarin Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.9 Sangamo Therapeutics
2.9.1 Sangamo Therapeutics Details
2.9.2 Sangamo Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Sangamo Therapeutics SWOT Analysis
2.9.4 Sangamo Therapeutics Product and Services
2.9.5 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.10 Ultragenyx Pharmaceutical
2.10.1 Ultragenyx Pharmaceutical Details
2.10.2 Ultragenyx Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Ultragenyx Pharmaceutical SWOT Analysis
2.10.4 Ultragenyx Pharmaceutical Product and Services
2.10.5 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Mucopolysaccharidosis Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Mucopolysaccharidosis Therapeutics Players Market Share
3.2.2 Top 10 Mucopolysaccharidosis Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Mucopolysaccharidosis Therapeutics Revenue and Market Share by Regions
4.2 North America Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Mucopolysaccharidosis Therapeutics Revenue by Countries
5.1 North America Mucopolysaccharidosis Therapeutics Revenue by Countries (2015-2020)
5.2 USA Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Mucopolysaccharidosis Therapeutics Revenue by Countries
6.1 Europe Mucopolysaccharidosis Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Mucopolysaccharidosis Therapeutics Revenue by Countries
7.1 Asia-Pacific Mucopolysaccharidosis Therapeutics Revenue by Countries (2015-2020)
7.2 China Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Mucopolysaccharidosis Therapeutics Revenue by Countries
8.1 South America Mucopolysaccharidosis Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Mucopolysaccharidosis Therapeutics by Countries
9.1 Middle East & Africa Mucopolysaccharidosis Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Mucopolysaccharidosis Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Mucopolysaccharidosis Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Mucopolysaccharidosis Therapeutics Market Forecast by Type (2019-2024)
10.3 Intravenous Revenue Growth Rate (2015-2025)
10.4 Intracerebroventricular (ICV) Revenue Growth Rate (2015-2025)
11 Global Mucopolysaccharidosis Therapeutics Market Segment by Application
11.1 Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Mucopolysaccharidosis Therapeutics Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Clinic Revenue Growth (2015-2020)
11.5 Other Revenue Growth (2015-2020)
12 Global Mucopolysaccharidosis Therapeutics Market Size Forecast (2021-2025)
12.1 Global Mucopolysaccharidosis Therapeutics Market Size Forecast (2021-2025)
12.2 Global Mucopolysaccharidosis Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Mucopolysaccharidosis Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Mucopolysaccharidosis Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Mucopolysaccharidosis Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Mucopolysaccharidosis Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Mucopolysaccharidosis Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

...

【掲載企業】

Shire (Takeda Pharmaceutical Company Limited)、Abeona Therapeutics Inc.、REGENXBIO Inc.、Denali Therapeutics、Lysogene、ArmaGen、Genzyme Corporation、BioMarin、Sangamo Therapeutics、Ultragenyx Pharmaceutical

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のムコ多糖症治療薬市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)(Global Mucopolysaccharidosis Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025)]についてメールでお問い合わせはこちらでお願いします。